IMUGENE LIMITED (ASX:IMU) - Ann: Investor Webinar - Final HER-Vaxx Overall Survival Results, 62237527, page-19 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by SENARIS ↑

From FDA website:

Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions.
Determining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one. AIDS, Alzheimer’s, heart failure and cancer are obvious examples of serious conditions. However, diseases such as epilepsy, depression and diabetes are also considered to be serious conditions.
Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.
Any drug being developed to treat or prevent a condition with no current therapy obviously is directed at an unmet need. If there are available therapies, a fast track drug must show some advantage over available therapy, such as:

Showing superior effectiveness, effect on serious outcomes or improved effect on serious outcomes

Avoiding serious side effects of an available therapy

Improving the diagnosis of a serious condition where early diagnosis results in an improved outcome

Decreasing a clinical significant toxicity of an available therapy that is common and causes discontinuation of treatment

Ability to address emerging or anticipated public health need

A drug that receives Fast Track designation is eligible for some or all of the following:

More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval

More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers

Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met

Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA

Fast Track designation must be requested by the drug company. The request can be initiated at any time during the drug development process. FDA will review the request and make a decision within sixty days based on whether the drug fills an unmet medical need in a serious condition.
Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.

Expand

Another bio pharma got FDA fast track designation for their Osteoarthritis treatment, but they are in Phase 3 trials.
Just looked at this link and it does say sometimes Phase 2 can apply for NDA
https://www.google.com/amp/s/amp.ca...u-need-to-know/phases-of-clinical-trials.html

No.	Vol.	Price($)
23	882045	5.2¢

No.

Vol.

Price($)

882045

5.2¢

Price($)	Vol.	No.
5.3¢	457736	5

Price($)

Vol.

No.

5.3¢

457736

No.	Vol.	Price($)
23	882045	0.052
41	5236152	0.051
53	4313079	0.050
20	2433068	0.049
22	1017663	0.048

No.

Vol.

Price($)

882045

0.052

5236152

0.051

4313079

0.050

2433068

0.049

1017663

0.048

Price($)	Vol.	No.
0.053	457736	5
0.054	3413571	7
0.055	1230479	14
0.056	2492035	10
0.057	768784	9

Price($)

Vol.

No.

0.053

457736

0.054

3413571

0.055

1230479

0.056

2492035

0.057

768784

(20min delay)
Last 5.2¢		Change 0.000(0.00%)		Mkt cap ! $382.1M

Open	High	Low	Value	Volume
5.3¢	5.3¢	5.2¢	$160.0K	3.048M

Another bio pharma got FDA fast track designation for their...

Good habits matters when it comes to finances

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Fourfold skarn increase points the way to viable garnet project, says Pure

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Another bio pharma got FDA fast track designation for their...

Top Stories

Good habits matters when it comes to finances

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Fourfold skarn increase points the way to viable garnet project, says Pure

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News